Compound brief
Evidence brief. Not treatment advice or a safety clearance. Last evidence update: September 2026.
A pentapeptide ghrelin-receptor agonist selected for growth-hormone release with less cortisol and prolactin signal than older GHRPs in preclinical comparisons. It is not GHRH and does not bind the GHRH receptor.
Stacking it with CJC in forum talk combines two receptors. That is not one molecule.
GHSR, the ghrelin receptor, releases growth hormone by a path distinct from GHRH. Ipamorelin was picked because older ghrelin peptides also nudged cortisol and prolactin.
Downstream IGF-1 is still hepatic. Pairing it in forum talk with a GHRH analog is two receptors, then one liver response.
Forum themes are unverified. They do not outrank a study, and they are not a dose.
Cleaner GHRP claim · unverified
Forums prefer ipamorelin because older ghrelin peptides were said to raise cortisol and prolactin. That preference is a community rule of thumb. A head-to-head human endocrine panel was not extracted here.
Theme summarized from public discussion. Not a quoted post, not a trial, and not a dose.